The first adult participant with hereditary angioedema (HAE) has been dosed in STOP-HAE, a Phase 3 clinical trial evaluating the efficacy of ADARx Pharmaceuticals’ investigational therapy ADX-324. Designed as a long-acting preventive treatment, ADX-324 aims to reduce the frequency of swelling attacks while requiring fewer injections. The…
News
A man in the U.S. developed nonallergic angioedema on his tongue after he ran out of his blood-pressure medication and took his spouse’s lisinopril, another medication used to lower blood pressure, for two weeks. The man had experienced a swelling episode from lisinopril (brand name Qbrelis, among others), an…
Many patients in Brazil lack access to first-line treatments such as Takhzyro (lanadelumab) to prevent swelling attacks in hereditary angioedema (HAE), a study found. “Despite recent advances, access to first-line therapies for long-term prophylaxis of HAE attacks remains limited,” the researchers wrote. These limitations “may likely be encountered in…
Biocryst Pharmaceuticals is preparing to acquire Astria Therapeutics, and with it navenibart, a still-experimental, long-acting prophylactic (preventive) treatment that could improve care for people with hereditary angioedema (HAE) by reducing how often patients need injections. Navenibart is now in Phase 3 clinical testing, after earlier data…
For most people with hereditary angioedema (HAE) given on-demand treatment in clinical trials with the now-approved therapy Ekterly (sebetralstat), swelling attacks stopped getting worse within 20 minutes of the oral medication being administered. That’s according to new data that Kalvista Pharmaceuticals, Ekterly’s developer, shared earlier this month…
Patient enrollment has started at sites in the European Union for a global Phase 3 clinical trial evaluating the safety and efficacy of navenibart, an antibody-based therapy designed to prevent swelling attacks in people with hereditary angioedema (HAE). Dubbed ALPHA-ORBIT trial (NCT06842823), the pivotal trial is testing the…
Biocryst Pharmaceuticals has sold the European rights to Orladeyo (berotralstat), its approved oral therapy for preventing swelling attacks in people with hereditary angioedema (HAE), to the Italian pharmaceutical company Neopharmed Gentili. Under the terms of the deal, according to a Biocryst press release, the company “will…
Acquired angioedema was the first sign of an underlying extranodal marginal zone lymphoma (EMZL) — a type of non-Hodgkin lymphoma — in a 45-year-old woman, according to a case study. After a comprehensive evaluation involving cancer and immunology specialists, she received treatment with rituximab. The therapy resolved her…
Ekterly (sebetralstat) is now approved by both the European Commission and Swissmedic as an on-demand treatment to manage swelling attacks in people with hereditary angioedema (HAE), ages 12 and older. These new approvals, which come on the heels of similar approvals in the U.S. and the…
Patient enrollment has been completed in a global Phase 3 clinical trial that’s evaluating lonvoguran ziclumeran, also known as lonvo-z (NTLA-2002), a gene-editing therapy Intellia Therapeutics is developing to prevent swelling attacks in people with hereditary angioedema (HAE). Dubbed HAELO (NCT06634420), the trial — which…
Recent Posts
- 1 lonvo-z dose keeps most HAE patients attack-free up to 3 years
- For many of us, becoming a patient advocate wasn’t optional
- FDA extends Orladeyo approval to children as young as 2
- With chronic illness, we can’t brush off holiday stress so easily
- Abrupt danazol stop in HAE can cause temporary hepatitis: Study